You are here: Industry Insights > ICR

News List

ICR researchers identify potential new treatment for drug-resistant prostate cancer pharmatimes
January 13, 2021
Researchers from The Institute of Cancer Research, London (ICR) and the Royal Marsden NHS Foundation Trust have revealed the mechanism of action for a ‘promising’ new prostate cancer treatment.
ICR scientists create 3D protein structure for new therapy development pharmaceutical-technology
December 21, 2020
The UK Institute of Cancer Research, London (ICR) researchers have created a three-dimensional (3D) structure of a complex of molecules for new therapies.
Researchers warn pandemic could delay cancer advances ‘by almost a year’ pharmatimes
December 01, 2020
A new survey has detailed cancer researchers’ concerns that advances for patients could be delayed by nearly 18 months due to the impact of the COVID-19 pandemic.
New pricing models could improve access to innovative cancer drugs pharmatimes
November 10, 2020
A consensus panel has concluded that the NHS could improve patient access to new cancer drugs by varying the price it pays for different medicines depending on what disease they are used to treat.
ICR urges change as NICE rejects Keytruda plus chemotherapy pharmatimes
October 26, 2020
The Institute for Cancer Research (ICR) has called for change in the way immunotherapy drugs are researched and evaluated after the National Institute for Health and Care Excellence (NICE) handed MSD’s Keytruda plus chemotherapy a rejection.
ICR study combines precision medicines to treat drug-resistant cancers pharmatimes
September 17, 2020
Results from an early-stage trial demonstrate that using a combination of two precision medicines to target hard-to-treat cancers was safe and showed promise in a range of solid tumour types.
Immunotherapies could target aggressive pancreatic cancer, research indicates pharmatimes
September 04, 2020
Researchers have discovered that an aggressive form of pancreatic cancer 'hijacks' the immune system's response and therefore is more likely to respond to treatment with immunotherapy, raising hopes for new targets in the fight against the disease.
ICR/Cyclacel scientists discover new cancer drug pharmatimes
July 16, 2020
Researchers say they have discovered a new cancer drug with potential use against a range of cancers, including some blood cancers and solid tumours.
COVID-19 related delays to cancer treatment could cost thousands of lives, research shows pharmatimes
May 21, 2020
Scientists at the Institute of Cancer Research (ICR) are warning that delays to cancer surgery and other treatment caused by the COVID-19 pandemic could be linked to thousands of additional deaths in England.
ICR welcomes new advanced prostate cancer treatment guideline pharmatimes
May 08, 2020
The Institute of Cancer Research, London, has welcomed approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer.

Previous page 1 2 3 Next page